Boston Family Office LLC Has $2.83 Million Stake in Boston Scientific Corporation $BSX

Boston Family Office LLC boosted its holdings in Boston Scientific Corporation (NYSE:BSX) by 151.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 29,624 shares of the medical equipment provider’s stock after buying an additional 17,864 shares during the period. Boston Family Office LLC’s holdings in Boston Scientific were worth $2,825,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of BSX. Murphy & Mullick Capital Management Corp increased its stake in Boston Scientific by 200.0% in the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 170 shares in the last quarter. FWL Investment Management LLC acquired a new stake in shares of Boston Scientific during the second quarter worth $26,000. Swiss RE Ltd. bought a new position in Boston Scientific in the fourth quarter valued at $26,000. Colonial Trust Co SC grew its position in Boston Scientific by 502.2% in the third quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 231 shares in the last quarter. Finally, Bangor Savings Bank grew its position in shares of Boston Scientific by 94.7% in the 4th quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock valued at $28,000 after acquiring an additional 142 shares during the period. Institutional investors own 89.07% of the company’s stock.

Insider Activity at Boston Scientific

In related news, Director Cheryl Pegus acquired 1,770 shares of the firm’s stock in a transaction that occurred on Wednesday, May 20th. The stock was acquired at an average price of $56.49 per share, for a total transaction of $99,987.30. Following the completion of the acquisition, the director owned 1,770 shares of the company’s stock, valued at approximately $99,987.30. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director David C. Habiger acquired 2,250 shares of the firm’s stock in a transaction that occurred on Wednesday, May 20th. The shares were bought at an average price of $55.92 per share, with a total value of $125,820.00. Following the acquisition, the director directly owned 13,878 shares of the company’s stock, valued at $776,057.76. The trade was a 19.35% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought 9,800 shares of company stock valued at $554,012 over the last ninety days. Corporate insiders own 0.34% of the company’s stock.

Wall Street Analyst Weigh In

BSX has been the subject of a number of research reports. Royal Bank Of Canada restated an “outperform” rating on shares of Boston Scientific in a research note on Thursday, May 28th. Truist Financial cut their target price on shares of Boston Scientific from $85.00 to $64.00 and set a “buy” rating for the company in a research note on Thursday, June 4th. Argus upgraded shares of Boston Scientific to a “strong-buy” rating in a research note on Thursday, February 26th. Piper Sandler reiterated an “overweight” rating and issued a $65.00 price objective on shares of Boston Scientific in a research note on Friday. Finally, Stifel Nicolaus set a $75.00 price objective on shares of Boston Scientific in a research note on Wednesday, May 27th. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Boston Scientific presently has an average rating of “Moderate Buy” and a consensus price target of $85.08.

Boston Scientific Trading Down 0.7%

BSX opened at $46.83 on Friday. Boston Scientific Corporation has a 1-year low of $45.99 and a 1-year high of $109.50. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42. The company has a market cap of $69.60 billion, a P/E ratio of 19.59, a price-to-earnings-growth ratio of 0.89 and a beta of 0.56. The company has a fifty day moving average price of $56.37 and a two-hundred day moving average price of $74.95.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The firm had revenue of $5.20 billion for the quarter, compared to the consensus estimate of $5.19 billion. During the same quarter in the prior year, the company posted $0.75 earnings per share. The business’s revenue was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Analysts predict that Boston Scientific Corporation will post 3.36 EPS for the current fiscal year.

Boston Scientific declared that its board has approved a share repurchase plan on Monday, May 18th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical equipment provider to purchase up to 6.4% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s management believes its shares are undervalued.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Analysts remain constructive on Boston Scientific, with one note saying the stock could still rise sharply from current levels despite this year’s de-rating. Meet the Medtech Stock Wall Street Thinks Will Soar 65% Over the Next 12 Months
• Positive Sentiment: Boston Scientific may benefit from Penumbra’s newly FDA-cleared stroke thrombectomy platform, which one analyst said could add about $100 million in incremental revenue over time. Penumbra’s FDA nod for clot removal tech a win for Boston Scientific
• Positive Sentiment: BTIG stayed bullish on BSX, pointing to valuation and substantial upside potential despite the recent decline in the share price. BTIG Remains Bullish On Boston Scientific (BSX); Check Out What It Says About The Stock
• Positive Sentiment: Boston Scientific reported strong catheter study results, which could support confidence in its clinical pipeline and product adoption. Boston Scientific Corp (BSX) Reports Strong Success Rates From Catheter Study
• Neutral Sentiment: Erste Group trimmed its FY2026 and FY2027 EPS estimates slightly, a modest negative on expectations but not a major change to the broader consensus. Boston Scientific Corporation (NYSE:BSX) – Free Report
• Negative Sentiment: Boston Scientific has repeatedly walked back full-year 2026 guidance, and that ongoing uncertainty is pressuring the stock and contributing to its decline. Meet the Medtech Stock Wall Street Thinks Will Soar 65% Over the Next 12 Months
• Negative Sentiment: One Seeking Alpha piece argues the market is treating BSX like a “broken compounder,” reflecting skepticism that has weighed on the shares. Boston Scientific: The Market Is Pricing A Broken Compounder-We See A Reset One

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.